EmGenisys

Based in the US, EmGenisys is a biotech company specializing in innovative assisted reproductive technologies to improve animal productivity by selecting healthy embryos for transfer. EmGenisys, founded in 2019, focuses on biotechnology solutions for livestock producers. The company is headquartered in the United States and has raised a total of USD 1. 5 mn through one funding deal.

The latest funding round, a Seed round led by Grit Road Partners and including Ag Ventures Alliance and Tall Grass Ventures, occurred on July 23, 2025, enabling the company to advance its operations. The founder's background details are not provided. EmGenisys specializes in advanced assisted reproductive technologies (ARTs) that enhance animal productivity by selecting healthy embryos for transfer. Their core offering involves a data-driven, machine learning platform that assesses embryo health through a simple process: clients record a 30-second video of embryos in culture, which the platform analyzes to generate a comprehensive health report.

This innovative approach aims to reduce stress factors for livestock, increase profitability for producers, and contribute to overall industry efficiency. The company's technology serves a diverse client base, including livestock producers and veterinary services across North America and parts of Europe, providing significant benefits in sectors focused on large animal agriculture, particularly in cattle production. EmGenisys generates revenue through a service model that centers around the analysis of embryos for livestock producers. Clients engage with the company on a contractual basis, utilizing the embryo assessment platform to improve transfer outcomes.

Revenue is derived from service fees associated with each embryo analysis conducted, potentially supplemented by subscription models for ongoing access to the platform and its analytics features. Clients may also participate in partnerships that facilitate bulk transaction agreements, enhancing the affordability of the service while providing comprehensive support for improved reproductive outcomes. The pricing structure for services is tailored to meet the needs of commercial operations, ensuring that livestock producers can maximize their investment through improved embryo selection processes. In July 2025, EmGenisys raised USD 1.

5 mn in Seed funding, led by Grit Road Partners, to expedite technology commercialization and expansion. The company plans to enhance its platform and launch new products aimed at further improving embryo health assessments. Future market expansion is anticipated in additional regions of Europe beyond current operations, with strategies for entering new geographic markets aimed for implementation in the near future.